Surgical Robotics Leaders Merge in Strategic Acquisition

ST. LOUIS — Stereotaxis, a prominent innovator in robotic systems for minimally invasive endovascular interventions, has announced its definitive agreement to acquire Robocath, a French pioneer in robotic technologies for interventional cardiology and neurointerventions. This strategic move, unveiled on Monday, is poised to create a formidable, integrated platform for a broad spectrum of complex procedures, significantly bolstering Stereotaxis's market leadership.

The acquisition unites Stereotaxis's established expertise in computer-controlled magnetic navigation, which precisely guides interventional devices, with Robocath's advanced mechanical robotic systems designed for multi-device control at the patient's bedside. Industry observers suggest this fusion of complementary technologies aims to deliver next-generation solutions across electrophysiology, interventional cardiology, and neurointerventions, addressing a mounting demand for enhanced precision and efficiency in surgical settings.

David Fischel, Chairman and CEO of Stereotaxis, articulated the strategic rationale, emphasizing that Robocath represents a "highly strategic addition" that amplifies and accelerates his company's trajectory as a leading robotic platform for endovascular procedures. He highlighted the creation of a uniquely capable system that expands reach across interventional medicine, promising accelerated strategy, enhanced technological leadership, and attractive commercial synergies. Robocath, based in Rouen, France, has garnered attention for its R-One+ system, currently the sole commercially available robotic solution for percutaneous coronary interventions in Europe, with fifteen installations globally. The company is also developing a cutting-edge system capable of manipulating up to five devices simultaneously, having recently completed successful first-in-human trials in France.

Philippe Bencteux, Founder and CEO of Robocath, underscored the importance of joining Stereotaxis, citing the necessity of scale, complementary technologies, and strategic alignment to accelerate development and expand impact in rapidly growing markets increasingly receptive to robotics. The combined entity plans to expedite the development of Robocath’s next-generation system, with regulatory submissions anticipated in the United States and Europe within the next two years. Stereotaxis intends to integrate Robocath's systems with its proprietary hardware and software, including GenesisX, Synchrony, and SynX, enabling advanced functionalities such as operating room integration, automation, and remote procedures. The full story was initially reported by Benzinga.

This consolidation comes amid a period of intense innovation within the medical robotics sector, where companies are striving to enhance surgical outcomes, reduce invasiveness, and improve clinician ergonomics. The integration of magnetic and mechanical robotic capabilities could set a new benchmark for precision and control in delicate endovascular procedures, potentially transforming patient care by reducing procedural times and recovery periods. Such advancements are crucial as healthcare systems globally grapple with increasing demands for specialized interventions.

The combined technological prowess positions the new entity to pioneer further breakthroughs, solidifying its role at the forefront of the evolving landscape of robotic surgery and promising a future where complex medical interventions are both safer and more accessible.